The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127540771 12754077 1 I 20100423 20100514 20160916 20160916 EXP US-ROCHE-703724 ROCHE 52.00 YR M Y 89.60000 KG 20160916 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127540771 12754077 1 PS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) 10MG/KG OVER 30-90 MINUTES ON DAYS 1 AND 15,LAST DOSE-26 MAR 2010-CYCLE 2, DAY 15, DOSE HELD Y U 125085 950 MG/KG SOLUTION FOR INFUSION
127540771 12754077 2 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) Y U 125085 1900 MG/KG
127540771 12754077 3 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) CYCLE: 28 DAYS. FREQUENCY: ON DAYS 1, 8, 15 AND 22. LAST DOSE:16APR2010 CYCLE 3, DAY 8,DOSE HELD Y U 0 75 MG
127540771 12754077 4 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) RESTARTED Y U 0
127540771 12754077 5 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 75 MG
127540771 12754077 6 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 50 MG
127540771 12754077 7 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 100 MG
127540771 12754077 8 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 100 MG
127540771 12754077 9 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 75 MG
127540771 12754077 10 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 100 MG
127540771 12754077 11 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 100 MG
127540771 12754077 12 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 100 MG
127540771 12754077 13 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 100 MG
127540771 12754077 14 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) Y U 0 75 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127540771 12754077 1 Carcinoid tumour
127540771 12754077 3 Carcinoid tumour

Outcome of event

Event ID CASEID OUTC COD
127540771 12754077 OT
127540771 12754077 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
127540771 12754077 Anal ulcer
127540771 12754077 Hyperglycaemia
127540771 12754077 Hyperkalaemia
127540771 12754077 Hypertension
127540771 12754077 Hypokalaemia
127540771 12754077 Lower gastrointestinal haemorrhage
127540771 12754077 Proctalgia
127540771 12754077 Pulmonary haemorrhage
127540771 12754077 Rectal haemorrhage

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127540771 12754077 2 20100312 20100409 0